Mibg (123i) Curium Netherlands

Iobenguane (I-123), the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable radiopharmaceutical for intravenous use. It is employed in nuclear medicine to visualize sympathetic nerve activity for diagnostic purposes in selected patient groups. GNH USA supplies Mibg (123i) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Iobenguane (I-123) is used in nuclear‑medicine procedures that assess sympathetic innervation and catecholamine‑producing tumors. - Myocardial innervation imaging: visualizes cardiac sympathetic nerve distribution to evaluate autonomic function. - Pheochromocytoma detection: highlights catecholamine‑secreting adrenal tumors for accurate localization. - Neuroblastoma imaging: identifies sympathetic‑origin pediatric tumors and assesses disease extent.

Adverse reactions are generally mild but can occur after intravenous administration.

Common Side Effects: - Injection site pain or erythema - Nausea or mild vomiting - Transient headache - Flushing or warmth sensation - Mild hypotension - Dizziness or light‑headedness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Significant hypotension requiring intervention - Radiation‑induced thyroid dysfunction - Bone‑marrow suppression with prolonged exposure - Severe arrhythmias in patients with underlying cardiac disease - Acute renal impairment in susceptible individuals

Prior to use, clinicians should evaluate patient‑specific factors that may affect safety or image quality. - Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk. - Breastfeeding: discontinue nursing for an appropriate interval after administration. - Thyroid blocking: consider potassium iodide pretreatment to reduce thyroid uptake of free iodine. - Renal function: assess because the tracer is excreted renally and impaired function may increase radiation exposure. - Concomitant norepinephrine‑modulating drugs: may alter tracer distribution and affect image interpretation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane (I‑123) may have interactions that influence tracer uptake or patient safety.

Major Interactions (Avoid): - Thyroid blocking agents (e.g., potassium iodide) that compete for iodine uptake and reduce image quality. - Strong norepinephrine transporter inhibitors (e.g., reserpine, certain antidepressants) that markedly diminish tracer accumulation. - High‑dose radiopharmaceuticals administered within 24 hours, which can increase cumulative radiation dose.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart‑rate response during cardiac imaging. - Calcium‑channel blockers: can modestly affect myocardial perfusion patterns. - Other diagnostic radiotracers given in close succession: may cause cross‑interference on imaging results.